Clinical Trial (Research) in Sri Lanka – ENRICH AF
ENRICH AF is investigating whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) in high-risk atrial fibrillation (CHA2DS2-VASc ≥2) patients with previous intracranial hemorrhage (Clinical Trials Gov Identifier NCT03950076).
Investigators from Sri Lanka and team RemediumOne joined a productive discussion with collegues from India and Nepal. Meeting held in Delhi India. An in-person Investigators meeting cannot be replaced by virtual. The degree of introductions and interactions are excellent in in-person meetings.